Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
For more information on any of the protocols listed below, please contact:
Amar Gajjar, MD
Director of Neuro-Oncology
Tabatha Doyle, RN
Coordinator, Brain Tumor Program
Contact us anytime, 24 hours a day, 7 days a week.
A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma after Radical Resection
For: Craniopharyngioma
Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants with Diffuse Intrinsic Pontine Glioma and High-Grade Glioma
For: Progressive or recurrent pontine glioma or high-grade glioma
Phase I Study of Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma
For: Newly diagnosed diffuse Intrinsic Pontine glioma and recurrent / progressive high grade glioma including diffuse intrinsic pontine glioma
A Phase I Study of 5-Fluorouracil In Children And Young Adults With Recurrent Ependymoma
For: Recurrent ependymoma
Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma
For: Embryonal brain tumors, choroid plexus carcinoma or ependymoma
Non St. Jude Protocols
A Phase I Study Of The C-Met Inhibitor Tivantinib (ARQ 197, IND#112603) In Children With Relapsed or Refractory Solid Tumors (ADVL1111)
For: Relapsed or refractory solid tumors or brain tumors
A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Tumor (SCUSF 0901; ACCL0922) Site CTEP ID= TN024
For: Previously treated brain tumors
A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients - A Children’s Oncology Group (COG) Study (ACNS1021)
For: Recurrent, refractory or progressive glioma and ependymoma
A Phase II Randomized Trial of Lenalidomide (NSC#703813, IND#70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas
For: Recurrent, refractory or progressive brain tumors
Phase II Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors
For: Newly diagnosed localize primary NGGCT or newly diagnosed localized germinoma
A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas
For: Newly diagnosed high grade gliomas
Phase III Randomized Trial of Maintenance Chemotherapy Versus Observation in Pediatric Patients (ages 1 to 21 yrs) With Newly Diagnosed Ependymoma Following Induction Chemotherapy and Post-Operative Radiation Therapy
For: Intracranial ependymoma
Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
For: Diffuse intrinsic pontine gliomas
Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma/ Brain Tumor
For: Gliomas
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma
For: Recurrent or refractory medulloblastoma
A Phase I /II Study of ABT-888, an Oral Poly (ADP-Ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, followed by ABT-888 and Temozolomide (TMZ), in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
For: newly diagnosed diffuse intrinsic pontine gliomas (DIPG)
